BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim Y, Chung WC. Bismuth-containing Standard Triple Therapy the First-line Eradication Therapy for Helicobacter pylori. Korean J Helicobacter Up Gastrointest Res 2021;21:354-8. [DOI: 10.7704/kjhugr.2021.0027] [Reference Citation Analysis]
2 Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, Wu J, Wang Y, Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter 2020;25:e12721. [PMID: 32656891 DOI: 10.1111/hel.12721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 2020;25:e12679. [PMID: 31958193 DOI: 10.1111/hel.12679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
6 Shetty V, Lamichhane B, Tay CY, Pai GC, Lingadakai R, Balaraju G, Shetty S, Ballal M, Chua EG. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut Pathog. 2019;11:21. [PMID: 31110563 DOI: 10.1186/s13099-019-0305-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
8 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility‐guided therapy for Helicobacter pylori ‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies. Helicobacter 2020;25. [DOI: 10.1111/hel.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Zahid R, Akram M, Riaz M, Munir N, Shehzad M. Phytotherapeutic modalities for the management of Helicobacter pylori associated peptic ulcer. Eur J Inflamm 2020;18:205873922096830. [DOI: 10.1177/2058739220968308] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Shahbazi MA, Faghfouri L, Ferreira MPA, Figueiredo P, Maleki H, Sefat F, Hirvonen J, Santos HA. The versatile biomedical applications of bismuth-based nanoparticles and composites: therapeutic, diagnostic, biosensing, and regenerative properties. Chem Soc Rev 2020;49:1253-321. [PMID: 31998912 DOI: 10.1039/c9cs00283a] [Cited by in Crossref: 76] [Cited by in F6Publishing: 14] [Article Influence: 38.0] [Reference Citation Analysis]
12 O'Connor A, Liou JM, Gisbert JP, O'Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter 2019;24 Suppl 1:e12640. [PMID: 31486235 DOI: 10.1111/hel.12640] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
13 Ikram M, Wakeel M, Hassan J, Haider A, Naz S, Ul-Hamid A, Haider J, Ali S, Goumri-Said S, Kanoun MB. Impact of Bi Doping into Boron Nitride Nanosheets on Electronic and Optical Properties Using Theoretical Calculations and Experiments. Nanoscale Res Lett 2021;16:82. [PMID: 33978872 DOI: 10.1186/s11671-021-03542-x] [Reference Citation Analysis]
14 Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter 2020;25:e12686. [PMID: 32173974 DOI: 10.1111/hel.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Li H, Xia XJ, Zhang LF, Chi JS, Liu P, Wu H, Xie XR, Tian DL, Kun KX, Gong RJ, Liu XM, Xu CX. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study. Eur J Gastroenterol Hepatol 2021;32:194-200. [PMID: 32804837 DOI: 10.1097/MEG.0000000000001896] [Reference Citation Analysis]
16 Leow AH, Azmi AN, Loke M, Vadivelu J, Graham DY, Goh K. Optimizing first line 7‐day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci 2020;65:3639-46. [DOI: 10.1007/s10620-020-06115-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Reference Citation Analysis]